PMID- 9083159
OWN - NLM
STAT- MEDLINE
DCOM- 19970411
LR  - 20190620
IS  - 0008-543X (Print)
IS  - 0008-543X (Linking)
VI  - 79
IP  - 7
DP  - 1997 Apr 1
TI  - Breast-conserving therapy for stage I-II synchronous bilateral breast carcinoma.
PG  - 1362-9
AB  - BACKGROUND: Synchronous bilateral breast carcinoma (SBBC) is an uncommon 
      presentation, and the management of patients with this disease is not well 
      established. METHODS: In order to evaluate whether patients with early-stage SBBC 
      could be safely and effectively treated with bilateral breast-conserving therapy 
      (BCT), the authors retrospectively reviewed the records of 24 patients with 
      clinical Stage I-II SBBC treated during the period 1977-1989 with bilateral BCT. 
      SBBC was defined as bilateral invasive carcinomas diagnosed no more than 1 month 
      apart. The median age at diagnosis was 56 years (range, 32-85 years), and the 
      median follow-up for surviving patients was 95 months (range, 68-157 months). 
      Pathology slides were available for review in 19 cases. Cosmetic results and 
      complications after BCT were scored. Outcome was compared with that of 1314 
      patients with unilateral Stage I or II breast carcinoma, within the same age 
      range, treated during the same time period. RESULTS: There were no significant 
      differences between the SBBC and unilateral groups in actuarial disease free 
      survival (70% and 74%, respectively, at 5 years), overall survival (88% and 87%, 
      respectively, at 5 years), or crude distribution of sites of first failure. 
      Multivariate analysis of overall survival and disease free survival also did not 
      show bilaterality to be a significant factor. The cosmetic results for the SBBC 
      group were not significantly different from those for the unilateral group. 
      Physician assessment of cosmetic outcome was excellent in 57% and good in 43% of 
      SBBC patients evaluated 25-48 months after BCT. Long term complications were rare 
      in both groups. CONCLUSIONS: Patients with early-stage SBBC can be safely treated 
      with carefully planned, bilateral BCT, with outcome that appears to be comparable 
      to that of patients with early-stage unilateral breast carcinoma.
FAU - Gollamudi, S V
AU  - Gollamudi SV
AD  - Department of Radiation Oncology, Harvard Medical School, Boston, Massachusetts, 
      USA.
FAU - Gelman, R S
AU  - Gelman RS
FAU - Peiro, G
AU  - Peiro G
FAU - Schneider, L J
AU  - Schneider LJ
FAU - Schnitt, S J
AU  - Schnitt SJ
FAU - Recht, A
AU  - Recht A
FAU - Silver, B J
AU  - Silver BJ
FAU - Harris, J R
AU  - Harris JR
FAU - Connolly, J L
AU  - Connolly JL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
SB  - IM
MH  - Adenocarcinoma/*surgery
MH  - Adult
MH  - Aged
MH  - Breast Neoplasms/*surgery
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - *Mastectomy, Segmental
MH  - Middle Aged
MH  - *Neoplasms, Multiple Primary
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 1997/04/01 00:00
MHDA- 2000/06/20 09:00
CRDT- 1997/04/01 00:00
PHST- 1997/04/01 00:00 [pubmed]
PHST- 2000/06/20 09:00 [medline]
PHST- 1997/04/01 00:00 [entrez]
AID - 10.1002/(SICI)1097-0142(19970401)79:7<1362::AID-CNCR14>3.0.CO;2-Y [pii]
AID - 10.1002/(sici)1097-0142(19970401)79:7<1362::aid-cncr14>3.0.co;2-y [doi]
PST - ppublish
SO  - Cancer. 1997 Apr 1;79(7):1362-9. doi: 
      10.1002/(sici)1097-0142(19970401)79:7<1362::aid-cncr14>3.0.co;2-y.